Prevalence of Depression and Anxiety Among Breast Cancer Patients

Completed

• Conditions: Breast Cancer; Anxiety; Depression

• Registration Number: NCT05011409
• Lead Sponsor: Kazakh Medical University of Continuing Education

Brief Summary

Depression and anxiety in patients with breast cancer is serious comorbidity that affects the quality of life for patients, and their survival rates as they have poorer health outcomes. Furthermore, patients' high psychological burden is linked to higher healthcare costs. The investigation of the depression and anxiety symptoms prevalence among newly diagnosed breast cancer patients will help to navigate the health policy adjustment and psycho-social support system requirements. This study aims to investigate the prevalence of depression and anxiety symptoms among newly diagnosed breast cancer patients in Almaty, Kazakhstan, and associated risk factors.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-17
• Study First Submitted: 2021-05-19
• Study First Submitted QC: 2021-08-17
• Study First Posted: 2021-08-18
• Primary Completion: 2022-02-21
• Status Verified: 2022-03
• Study Completion: 2022-03-10
• Last Update Submitted: 2022-03-24
• Last Update Posted: 2022-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 162

Inclusion Criteria

• Female adults with confirmed diagnosis of breast cancer within the 6 months study enrollment
• TNM stage I-IV
• Russian or Kazakh language proficiency
• Ability to provide informed consent

Exclusion Criteria

• Current psychotic disorder, manic episode, serious neurological disorder, intellectual disability, or developmental disorder
• Current active suicidal ideation
• Referral to palliative care

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of Depression Symptoms	within 6 months of diagnosis	Prevalence of depression symptoms among newly diagnosed breast cancer patients according to the Beck Depression Inventory-II (BDI-II). The 21-item self-administered survey is scored on a scale of 0-3 in a list of four statements arranged in increasing severity about a particular symptom of depression. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the Beck Depression Inventory-II (BDI-II). There is a four-point scale for each item ranging from 0 to 3. p. On two items (16 and 18) there are seven options to indicate either an increase or decrease of appetite and sleep. Cut-off score guidelines for the BDI-II are given with the recommendation that thresholds be adjusted based on the characteristics of the sample, and the purpose for use of the BDI-II. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
Prevalence of Anxiety Symptoms	within 6 months of diagnosis	Prevalence of anxiety symptoms among newly diagnosed breast cancer patients according to the Beck Anxiety Inventory. The Beck Anxiety Inventory (BAI) consists of 21 self-reported items (four-point scale ranging from 0 to 3. p.) used to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63).

Trial Locations

Locations (2)

Almaty Oncology Center; 🇰🇿 Almaty, Kazakhstan

Kazakh Institute of Oncology and Radiology; 🇰🇿 Almaty, Kazakhstan